WORCESTER, Mass., March 2, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) today announced that it has received notice of issuance of a patent in respect of its Ii-Key peptide vaccine technology in China. This expands a solid intellectual property estate that includes both broad claims covering its platform technologies as well as specific Ii-Key-containing drug development compounds. Additionally, management is actively seeking potential joint venture/licensing partnerships for its peptide cancer vaccine technology platform and is in active discussions with several large pharmaceutical companies in that respect.
